Kyverna Therapeutics (KYTX) Non Operating Income (2023 - 2026)

Kyverna Therapeutics' Non Operating Income history runs 4 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• Quarterly Non Operating Income fell 40.89% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (down 51.52% YoY) and the FY2025 annual result came in at $8.5 million, down 43.68% from the prior year.
• Non Operating Income was $1.6 million for Q1 2026 at Kyverna Therapeutics, up from $1.5 million in the prior quarter.
• Across five years, Non Operating Income topped out at $4.6 million in Q2 2024 and bottomed at $211000.0 in Q2 2023.
• A 4-year average of $2.1 million and a median of $1.9 million in 2025 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2024 — Non Operating Income soared 2095.26% — and 2025, when it slumped 58.39%.
• Kyverna Therapeutics' Non Operating Income stood at $710000.0 in 2023, then surged by 400.28% to $3.6 million in 2024, then slumped by 58.39% to $1.5 million in 2025, then increased by 10.89% to $1.6 million in 2026.
• Business Quant data shows KYTX's Non Operating Income at $1.6 million in Q1 2026, $1.5 million in Q4 2025, and $1.9 million in Q3 2025.